Capital International Investors raised its stake in shares of Abbott Laboratories (NYSE:ABT) by 2.9% during the 4th quarter, Holdings Channel.com reports. The institutional investor owned 47,327,202 shares of the healthcare product maker’s stock after acquiring an additional 1,328,056 shares during the quarter. Abbott Laboratories comprises 1.4% of Capital International Investors’ portfolio, making the stock its 12th biggest holding. Capital International Investors’ holdings in Abbott Laboratories were worth $4,110,841,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
A number of other hedge funds and other institutional investors also recently bought and sold shares of ABT. MV Capital Management Inc. boosted its position in shares of Abbott Laboratories by 7.3% during the 3rd quarter. MV Capital Management Inc. now owns 7,888 shares of the healthcare product maker’s stock worth $660,000 after acquiring an additional 537 shares in the last quarter. Headinvest LLC boosted its position in shares of Abbott Laboratories by 9.7% during the 3rd quarter. Headinvest LLC now owns 12,918 shares of the healthcare product maker’s stock worth $1,081,000 after acquiring an additional 1,142 shares in the last quarter. SWS Partners acquired a new stake in shares of Abbott Laboratories during the 3rd quarter worth approximately $2,718,000. Vestor Capital LLC boosted its position in shares of Abbott Laboratories by 3.6% during the 3rd quarter. Vestor Capital LLC now owns 185,232 shares of the healthcare product maker’s stock worth $15,498,000 after acquiring an additional 6,396 shares in the last quarter. Finally, J.P. Marvel Investment Advisors LLC acquired a new stake in shares of Abbott Laboratories during the 3rd quarter worth approximately $5,918,000. Institutional investors own 75.02% of the company’s stock.
In other news, EVP Andrea F. Wainer sold 1,120 shares of the firm’s stock in a transaction on Friday, February 7th. The shares were sold at an average price of $88.61, for a total transaction of $99,243.20. Following the completion of the transaction, the executive vice president now owns 40,140 shares of the company’s stock, valued at $3,556,805.40. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, VP Philip P. Boudreau sold 10,600 shares of the firm’s stock in a transaction on Friday, March 13th. The shares were sold at an average price of $82.00, for a total transaction of $869,200.00. Following the transaction, the vice president now directly owns 22,463 shares of the company’s stock, valued at approximately $1,841,966. The disclosure for this sale can be found here. Insiders have sold 568,733 shares of company stock valued at $50,878,762 in the last ninety days. Insiders own 1.70% of the company’s stock.
A number of brokerages have weighed in on ABT. Citigroup began coverage on shares of Abbott Laboratories in a research report on Wednesday, March 4th. They issued a “buy” rating and a $96.00 target price on the stock. UBS Group raised their target price on shares of Abbott Laboratories from $99.00 to $105.00 and gave the company a “buy” rating in a research report on Thursday, January 23rd. Guggenheim lowered shares of Abbott Laboratories from a “buy” rating to a “neutral” rating in a research report on Thursday, January 2nd. Credit Suisse Group cut their target price on shares of Abbott Laboratories from $104.00 to $94.00 and set an “outperform” rating on the stock in a research report on Friday, March 6th. Finally, Raymond James raised their target price on shares of Abbott Laboratories from $90.00 to $99.00 and gave the company an “outperform” rating in a research report on Thursday, January 23rd. One research analyst has rated the stock with a sell rating, six have given a hold rating and twelve have assigned a buy rating to the company. The stock currently has an average rating of “Buy” and a consensus target price of $96.13.
Shares of ABT stock traded up $4.20 during trading hours on Thursday, hitting $74.95. 3,084,865 shares of the company’s stock traded hands, compared to its average volume of 12,224,732. The stock’s 50 day simple moving average is $81.95 and its 200 day simple moving average is $84.07. The stock has a market cap of $122.89 billion, a PE ratio of 36.38, a price-to-earnings-growth ratio of 1.83 and a beta of 1.17. Abbott Laboratories has a 12 month low of $61.61 and a 12 month high of $92.45. The company has a quick ratio of 1.04, a current ratio of 1.44 and a debt-to-equity ratio of 0.53.
Abbott Laboratories (NYSE:ABT) last released its quarterly earnings results on Wednesday, January 22nd. The healthcare product maker reported $0.95 earnings per share (EPS) for the quarter, meeting the Thomson Reuters’ consensus estimate of $0.95. The firm had revenue of $8.31 billion during the quarter, compared to the consensus estimate of $8.26 billion. Abbott Laboratories had a net margin of 11.56% and a return on equity of 18.39%. The company’s revenue for the quarter was up 7.1% on a year-over-year basis. During the same quarter last year, the firm earned $0.81 earnings per share. As a group, equities research analysts expect that Abbott Laboratories will post 3.6 EPS for the current fiscal year.
The firm also recently declared a quarterly dividend, which will be paid on Friday, May 15th. Stockholders of record on Wednesday, April 15th will be paid a dividend of $0.36 per share. The ex-dividend date of this dividend is Tuesday, April 14th. This represents a $1.44 annualized dividend and a dividend yield of 1.92%. This is an increase from Abbott Laboratories’s previous quarterly dividend of $0.08. Abbott Laboratories’s dividend payout ratio (DPR) is presently 44.44%.
Abbott Laboratories Company Profile
Abbott Laboratories discovers, develops, manufactures, and sells health care products worldwide. The company's Established Pharmaceutical Products segment offers branded generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency; irritable bowel syndrome or biliary spasm; intrahepatic cholestasis or depressive symptom; gynecological disorder; hormone replacement therapy; dyslipidemia; hypertension; hypothyroidism; Ménière's disease and vestibular vertigo; pain, fever, and inflammation; migraine; and anti-infective clarithromycin, as well as provides influenza vaccines and products that regulate physiological rhythm of the colon.
Recommended Story: What is basic economics?
Want to see what other hedge funds are holding ABT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Abbott Laboratories (NYSE:ABT).
Receive News & Ratings for Abbott Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abbott Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.